Comparison of monitoring methods for lepirudin: Impact of warfarin and lupus anticoagulant

Salmela, Birgitta; Joutsi‐Korhonen, Lotta; Saarela, Ellen; Lassila, Riitta

doi:10.1016/j.thromres.2010.02.002

Cited by 11 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 Others have used plasma samples drawn from patients receiving a single DTI (lepirudin). 22 Unlike the other studies, the current study used plasma samples drawn from patients receiving several different drugs at a single institution and is representative of daily laboratory practice.…”

Section: Discussionmentioning

confidence: 99%

“…A third is that the samples were deidentified, which prevented us from determining and a factor V-activating protein to generate the prothrombinase complex and is not influenced by the plasma content of coagulation proteins other than factor V, factor II, and fibrinogen (although it is affected by lupus anticoagulants). 22 We hypothesized that it might provide a better estimate of plasma DTI content than the aPTT, which may be influenced by the concentration of a number of additional plasma proteins (notably those in the intrinsic and contact pathways). Indeed, the PiCT correlated to a higher degree with both the dTT and the chromogenic ECA than did the aPTT.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples

Lind

Boyle

Fisher

et al. 2014

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples

Lind

Boyle

Fisher

et al. 2014

American Journal of Clinical Pathology

View full text Add to dashboard Cite

show abstract

“…PiCT assay is sensitive to both FXa and thrombin inhibitors [10][11][12][13]. Anti-Xa activity was measured with Berichrom Heparin chromogenic assay (Siemens Healthcare Diagnostics) and PiCT with Pefakit PiCT (DSM Nutritional Products Ltd., Branch Pentapharm, Basel, Switzerland).…”

Section: Blood Samplesmentioning

confidence: 99%

Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement

Virtanen

Salmela²,

Leinonen³

et al. 2014

Blood Coagulation &Amp; Fibrinolysis

Self Cite

View full text Add to dashboard Cite

Fondaparinux, indirect factor Xa (FXa) inhibitor, is recommended for thromboprophylaxis for high-risk patients undergoing major orthopedic surgery. We evaluated the prothrombotic state and anticoagulant intensity of fondaparinux (2.5 mg daily) after total hip replacement (THR). Twenty patients underwent THR - seven bilateral and 13 unilateral. Blood samples were collected preoperatively and at 6 h, 8 h (2 h after fondaparinux), 1 day (12-14 h after fondaparinux), and 4 weeks (12-14 h after fondaparinux) postoperatively. Antithrombin (AT), fibrinogen, factor VIII activity, coagulation times, thrombin-AT (TAT) complex, D-dimer, C-reactive protein, prothrombinase-induced clotting time (PiCT) and anti-Xa activity were measured. The latter two were also tested after plasma spiking with fondaparinux 0-1.25 μg/ml. In spiked prophylactic fondaparinux samples (0-0.25 μg/ml), PiCT and anti-Xa activity correlated (r = 0.84) better than in the patient samples (r = 0.35). On the first day, anti-Xa activity and PiCT dissociated, and PiCT lost sensitivity for fondaparinux. AT decreased but stayed within the normal range, whereas TAT complex and D-dimer peaked at 6 h as signs of thrombin generation. On the first postoperative day, TAT and D-dimer halved. Bilateral THR associated with higher TAT and D-dimer levels up to 4 weeks. Perioperative FVIII levels were not affected, but were elevated in both groups (range 191-211%) after 4 weeks. Anti-Xa activity detected prophylactic fondaparinux with higher sensitivity than PiCT in vitro, but even more so in vivo. Thus, PiCT is not the method of choice to assess fondaparinux at least in association with THR. THR, bilateral more than unilateral, increased thrombin generation and D-dimer 7-11-fold early after surgery. Factor VIII activity and D-dimer remained elevated even after 4 weeks despite the compliant thromboprophylaxis with fondaparinux.

show abstract

“…Thrombin time (TT) is linear, highly sensitive, and can be calibrated with Dabi to depict its effects [10]. Chromogenic ecarin clotting assay (ECA®) uses the snake venom ecarin to generate meizothrombin, [11][12][13] with less interferences with, e.g., lupus anticoagulant and warfarin than clot-based assays [14]. TT calibrated with Dabi, Hemoclot® Thrombin Inhibitors (HTI®), and ECA® correlate well with actual Dabi concentrations in plasma as measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), whereas correlations with APTT are modest and with PT non-existent [8,9].…”

Section: Introductionmentioning

confidence: 99%

From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples

Helin

Lemponen

Hjemdahl

et al. 2015

Thrombosis Research

Self Cite

View full text Add to dashboard Cite

Comparison of monitoring methods for lepirudin: Impact of warfarin and lupus anticoagulant

Cited by 11 publications

References 34 publications

Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples

Comparison of the aPTT With Alternative Tests for Monitoring Direct Thrombin Inhibitors in Patient Samples

Laboratory-monitored fondaparinux and coagulation activity in association with total hip replacement

From laboratory to clinical practice: Dabigatran effects on thrombin generation and coagulation in patient samples

Contact Info

Product

Resources

About